Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Amphastar Pharmaceuticals stock retook its 50-day moving average, but is not currently near a proper buy point. Look for the stock to form and break out of a new chart pattern.
Looking For The Best Stocks To Buy And Watch? Start Here
The biotech stock earns a 98 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth tops 98% of all stocks.
Its Accumulation/Distribution Rating of D- shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
Amphastar Sees Top, Bottom Line Growth
In Q1, the company reported 74% EPS growth. Top line growth came in at 17%, down from 26% in the previous quarter.
Amphastar Pharmaceuticals stock earns the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals is the top-ranked stock within the group.
